Drug – bio-affecting and body treating compositions – Designated organic active ingredient containing – Having -c- – wherein x is chalcogen – bonded directly to...
Reexamination Certificate
2008-09-22
2011-10-18
Dentz, Bernard (Department: 1622)
Drug, bio-affecting and body treating compositions
Designated organic active ingredient containing
Having -c-, wherein x is chalcogen, bonded directly to...
Reexamination Certificate
active
08039510
ABSTRACT:
The present invention discloses methods of making a mixture of theaflavin, theaflavin-3-gallate, theaflavin-3′-gallate and theaflavin 3,3′-digallate, pharmaceutical compositions of the above mixture of theaflavins, diet supplement compositions of the above mixture of theaflavins and methods for using the above mixtures of theaflavin and pharmaceutical compositions thereof to treat or prevent various diseases. The present invention also discloses methods of making theaflavin, theaflavin-3-gallate, theaflavin-3′-gallate and theaflavin 3,3′-digallate, each as a separate compound, pharmaceutical compositions of the above compounds, diet supplement compositions of the above compounds and methods for using the above compounds to treat or prevent various diseases.
REFERENCES:
patent: 2975057 (1961-03-01), Seltzer et al.
patent: 3228789 (1966-01-01), Glassman
patent: 3845770 (1974-11-01), Theeuwes et al.
patent: 3916899 (1975-11-01), Theeuwes et al.
patent: 4708834 (1987-11-01), Cohen et al.
patent: 4840966 (1989-06-01), Hara et al.
patent: 4935243 (1990-06-01), Borkan et al.
patent: 5318986 (1994-06-01), Hara et al.
patent: 5698155 (1997-12-01), Grosswald et al.
patent: 5879730 (1999-03-01), Bouwens et al.
patent: 6602527 (2003-08-01), Slaga et al.
patent: 7157493 (2007-01-01), Zhao et al.
patent: 7427622 (2008-09-01), Zhao et al.
patent: 2004/0097432 (2004-05-01), Roh-Schmidt et al.
patent: 19627344 (1999-03-01), None
patent: 0423419 (1991-04-01), None
patent: 1106640 (1968-03-01), None
patent: 1413351 (1975-11-01), None
patent: 46-9238 (1971-03-01), None
patent: 48-82098 (1973-11-01), None
patent: 63-214183 (1988-09-01), None
patent: 3-133928 (1991-06-01), None
patent: 6-256180 (1994-09-01), None
patent: 2000-327572 (2000-11-01), None
patent: WO 01/93886 (2001-12-01), None
“Black and Green Tea: How do they differ?”, Tea Health Facts, pp. 1-4, Sep. 3, 2002, http://www.teahealth.co.uk/th/facts/1.htm.
“Camellia sinensis(Tea)”, Biodiversity explorer, pp. 1-6, Sep. 5, 2002, http://www.museums.org.za/bio/plants/theaceae/camellia—sinesis.htm.
“Herbs—Green Tea (Camellia sinensis)”, Golden Temple Ingredients-Herbs-Green Tea (Camellia sinensis), pp. 1-3, Sep. 5, 2002, http://www.goldentemple.com/Clients/KIIT/GT/Ingredients.nsf/Ingredients/Green+Tea+(Camellia....
“Tea Polyphenols, water soluble, lipid soluble”, Wuzhou International Co., Ltd., one-page, Sep. 5, 2002, http://www.chinax.com/pages/wuzhou/tea%20polyphenols.htm.
Abe et al., “Black Tea Theaflavins Are Potent Inhibitors of Squalene Epoxidase, A Key Enzyme in Cholesterol Biosynthesis,” Japanese Journal of Food Chemistry, vol. 7(1), p. 47-50 (2000).
Alderman, “A Review of Cellulose Ethers in Hydrophilic Matrices for Oral Controlled-Release Dosage Forms,” Int. J. Phann. Tech. Prod. Mfr. 5(3):1-9, 1984.
Bamba et al., “Release mechanisms in gelfonning sustained release preparations,” Int. J. Phann. 2:307, 1979.
Berge et al., “Pharmaceutical Salts,” J. Phann. Sci. 66:1-19, 1977.
Bhagwat et al., “Flavonoid composition of tea: Comparison of black and green teas,” 1 page, USDA, Agricultural research Services.
Chemical Abstracts, “Preparation of tea pigments for pharmaceuticals,” vol. 120, No. 63, 1994, abstract No. 144138v, p. 691 col. 1, XP002312132.
Chemical Abstracts, vol. 127, No. 14, 1997, abstract No. 19OO4Oz, Ishikawa, T. “Effect of tea flavonoid supplementation on the susceptibility of low-density lipoprotein to oxidative modification”, p. 577, XP002312134.
Chemical Abstracts, vol. 127, No. 26, 1997, abstract No. 355154e, Meng. ME1: “Influence of theaflavin on blood lipid and hemorheologic parameters”, p. 25 col. 2, XP002312133.
Chung et al., “Mechanisms of inhibition of the Ras-MAP kinase signaling pathway in 30.7b Ras 12 cells by tea polyphenols (—)-epigallocatechin-3-gallate and theaflavin-3,3′-digallate,” FASEB Journal, vol. 15, No. 11, Sep. 2001 pp. 2022-2024, XP002312129.
Diepeveen et al., “Effects of atorvastatin and vitamin E on lipoproteins and oxidative stress in dialysis patients: a randomised-controlled trial,” J. Internal Medicine 257:438-445 (2005).
Dong et al., “Inhibition of Tumor Promoter-induced Activator Protein 1 Activation and Cell Transformation by Tea Polyphenols, (—)-Epigallocatechin Gallate, and theaflavins,” Cancer Research 57:4414-4419 (1997).
Eadington, “Tea Polyphenols and Cancer Prevention”, Eadington/SJBR/2000, pp. 1-5, Sep. 5, 2002, http://wwwchem.csustan.edu/chem4400/SJBR/00eading.htm.
Finger, “In-vitro studies on the effect of polyphenol oxidase and peroxidase on the formation of polyphenolic black tea constituents”, J. Sci Food Agric, vol. 66, No. 3, 1994, pp. 293-305, XP002312128.
Goodsall et al., “The mechanism of theaflavin oxidation during black tea manufacture”, 2ndInternational Electronic Conference on Synthetic Organic Chemistry (ECSOC-2), http://www/mdpi.org/ecsoc/, Sep. 1-30, 1998, pp. 1-3, http://ecsoc2.hcc.ru/DP—TOP2/dp119/dp119.htm.
Hashimoto, F. “Evaluation of tea polyphenols as anti-HIV agents”, Bioorganic and Medicinal Chemistry Letters, vol. 6, No. 6, 1996, pp. 695-700, XP004135008.
Information sheets concerning lowering of LDL, 2 pages.
Information sheets concerning oxidation of LDL, 3 pages.
Ishikawa et al., “Effect of tea flavonoid supplementation on the susceptibility of low-density lipoprotein to oxidative modification,” Am. J. Clin. Nutr. 66:261-266 (1997).
Leung et al., “Theaflavins in Black Tea and Catechins in Green Tea Are Equally Effective Antioxidants,” J. Nutr. 131(9):2248-2251, 2001.
Nomura et al., “Inhibition of 12-O-tetradecanoylphorbol-13-acetate-induced NF-κB activation by tea polyphenols, (—)-epigallocatechin gallate and theaflavins,” Carcinogenesis 21(10):1885-1890 (2000).
Patent Abstracts of Japan, 06256180, Taiyo Kagaku Co Ltd, Sep. 13, 1994.
Patent Abstracts of Japan, 11032725, Mitsui Norin KK, Feb. 9, 1999.
Robertson et al., “Effects of Physical and Chemical Conditions on the in Vitro Oxidation of Tea Leaf Catechins,” Phytochemistry 22(4):889-896 (1983).
Sarkar et al., “Black Tea is a Powerful Chemopreventor of Reactive Oxygen and Nitrogen Species: Comparison with Its Individual Catechin Constituents and Green Tea,” Biochem. Biophys. Res. Commun. 284(1):173-178, 2001.
Verma et al., “Osmotically Controlled Oral Drug Delivery,” Drug Dev. Ind. Pharm. 26:695-708, 2000.
Vinson et al., “Effect of green and black tea supplementation on lipids, lipid oxidation and fibrinogen in the hamster: mechanisms for the epidemiological benefits of tea drinking,” FEBS Letters 443:44-46 (1998).
Yang et al., “Inhibition of growth and induction of apoptosis in human cancer cell lines by tea polyphenols,” Carcinogenesis 19(4):611-616 (1998).
Yang et al., “The Chemistry of Tea”, p. 1-2, Sep. 5, 2002, http://www.teatalk.com/science/chemistry.htm.
Yoshida et al., “Inhibitory effect of tea flavonoids on the ability of cells to oxidize low density lipoprotein”, Biochemical Pharmacology, vol. 58, No. 11, 1999, pp. 1695-1703, XP002312131.
Yoshino et al., “Antioxidative Effects of Black Tea Theaflavins and Thearubigin on Lipid Peroxidation of Rat Liver Homogenates Induced by tert-Butyl Hydroperoxide,” Biol. Pharm. Bull. 17(1):146-149, 1994.
Chen Hu
Zhao Jian
Zhou Rui
Cooley LLP
Dentz Bernard
Nashai Biotech, LLC
LandOfFree
Methods of making and using theaflavin,... does not yet have a rating. At this time, there are no reviews or comments for this patent.
If you have personal experience with Methods of making and using theaflavin,..., we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Methods of making and using theaflavin,... will most certainly appreciate the feedback.
Profile ID: LFUS-PAI-O-4282007